AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 20723187
Drug: Vitamin D(3)
DrugBank: Vitamin D (DB11094)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D(3) supplementation (100,000 iu) along with antibiotics
Trial: 20723187
Drug: Placebo along
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo along with antibiotics
Trial: 14629655
Drug: Delipidated acid-treated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delipidated acid-treated M. vaccae (0.4 mg first dose, 0.8 mg second dose)
Trial: 8760546
Drug: Hyperbaric Oxygen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hyperbaric Oxygen therapy (HBO) - 100% O2 at 2.5 ata for 90 minutes, twice daily, over 6 days
Trial: 8760546
Drug: Placebo -
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo - 21% O2 at 1.1 ata for 90 minutes, twice daily, over 6 days
Trial: 8760546
Drug: Hyperbaric Oxygen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hyperbaric Oxygen therapy (HBO)
Trial: 1750819
Drug: Treatment (exact
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment (exact intervention not specified)
Trial: 29098247
Drug: Er:YAG laser
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Er:YAG laser as an adjunctive to scaling and root planning (SRP)
Trial: 21911313
Drug: Cryotherapy (holding
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cryotherapy (holding ice cubes in mouth before, during, and after chemotherapy)
Trial: 19434929
Drug: High-dose IFN‐α‐2b
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose IFN‐α‐2b induction therapy combined with amantadine and ribavirin for 6 weeks followed by weekly pegylated IFN‐α‐2b for 24 or 48 weeks
Trial: 19434929
Drug: High-dose IFN‐α‐2b
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose IFN‐α‐2b induction therapy
Trial: 17103193
Drug: 2 g-IVIG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 g-IVIG
Trial: 17103193
Drug: 1 g-IVIG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 g-IVIG
Trial: 17103193
Drug: 1 g-IVIG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 g-IVIG with additional IVIG
Trial: 11429399
Drug: Amiodarone (oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amiodarone (oral administration for 4 weeks)
Trial: 9599521
Drug: Inhaled budesonide
RxNorm normalized name: budesonide Inhalation Suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled budesonide (two inhalations of 1000 micrograms)
Trial: 12511310
Drug: Intramuscular dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intramuscular dexamethasone (0.6 mg/kg)
Trial: 2744928
Drug: Exercise at
RxNorm normalized name: rose bengal AT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exercise at 40% of maximal workload with carbohydrate feeding (25% maltodextrin-fructose solution) for 2.5 hours
Trial: 2744928
Drug: Rest for
RxNorm normalized name: Rest Simply
DrugBank: Diphenhydramine (DB01075)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Rest for 2.5 hours with carbohydrate feeding (25% maltodextrin-fructose solution)
Trial: 1253811
Drug: Aldosterone infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aldosterone infusion before fasting and on day 4 of fasting
Trial: 1253811
Drug: Spironolactone treatment
RxNorm normalized name: Spironolactone
DrugBank: Spironolactone (DB00421)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Spironolactone treatment (300 mg/day p.o.) on days 6 to 8 of the fast
Trial: 1253811
Drug: Glucose load
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glucose load (100 g) on day 7
Trial: 24482945
Drug: Intramuscular ACTH
RxNorm normalized name: ACTH
DrugBank: Corticotropin (DB01285)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intramuscular ACTH stimulation test using Acton Prolongatum (25 units injected intramuscularly)
Trial: 15910892
Drug: Ajulemic acid
RxNorm normalized name: Ajulemic acid
DrugBank: Lenabasum (DB12193)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ajulemic acid (AJA) 40 mg and 80 mg daily
Trial: 14522763
Drug: Oral acyclovir
RxNorm normalized name: Acyclovir
DrugBank: Acyclovir (DB00787)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral acyclovir 400 mg twice daily for 6 months
Trial: 14522763
Drug: Placebo tablets
RxNorm normalized name: placebo Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablets for 6 months
Trial: 10945510
Drug: Naftidrofuryl 600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naftidrofuryl 600 mg/d
Trial: 8803646
Drug: L-fenfluramine
RxNorm normalized name: DL-Fenfluramine
DrugBank: Fenfluramine (DB00574)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-fenfluramine
Trial: 8803646
Drug: D-amphetamine +
RxNorm normalized name: amphetamine / dextroamphetamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: D-amphetamine + L-fenfluramine
Trial: 6418300
Drug: Real electroconvulsive
RxNorm normalized name: REAL FOODS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Real electroconvulsive therapy
Trial: 6418300
Drug: Simulated electroconvulsive
RxNorm normalized name: bisacodyl
DrugBank: Bisacodyl (DB09020)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Simulated electroconvulsive therapy
Trial: 29127547
Drug: Magnesium and
RxNorm normalized name: Calcium, Magnesium and Zinc
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Magnesium and zinc co-supplementation (250 mg of magnesium oxide plus 220 mg of zinc sulfate containing 50 mg zinc)
Trial: 30336805
Drug: ZX008 0.8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ZX008 0.8 mg/kg
Trial: 30336805
Drug: STP regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: STP regimen (stiripentol 3,500 mg, clobazam 20 mg, valproate 25 mg/kg, max. 1,500 mg)
Trial: 30336805
Drug: ZX008 0.8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ZX008 0.8 mg/kg + STP regimen
Trial: 14614647
Drug: Metformin, thiazolidinediones,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin, thiazolidinediones, and acarbose
Trial: 14614647
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of metformin and thiazolidinediones with sulphonylureas or meglitinides
Trial: 9099461
Drug: High-dose adjuvant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose adjuvant CAF chemotherapy
Trial: 9099461
Drug: Standard-dose adjuvant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard-dose adjuvant CAF chemotherapy
Trial: 9099461
Drug: Low-dose adjuvant
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose adjuvant CAF chemotherapy
Trial: 8402326
Drug: Vitamin K
RxNorm normalized name: Vitamin K
DrugBank: Phylloquinone (DB01022)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin K (1 mg/day) for 2 weeks
Trial: 8402326
Drug: Vitamin K
RxNorm normalized name: Vitamin K
DrugBank: Phylloquinone (DB01022)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin K (1 mg/day) for 3 months
Trial: 8402326
Drug: Vitamin K
RxNorm normalized name: Vitamin K
DrugBank: Phylloquinone (DB01022)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin K (1 mg/day) for 3 months in fast losers of urinary calcium
Trial: 3081221
Drug: Ranitidine (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranitidine (150 mg twice daily for six weeks)
Trial: 27183454
Drug: Training general
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Training general practitioners (GPS) in optimizing HF medication
Trial: 18544642
Drug: Pioglitazone treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pioglitazone treatment for 10 weeks
Trial: 16447591
Drug: Periprostatic plexus
RxNorm normalized name: Bos taurus solar plexus preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Periprostatic plexus anesthesia (PPA) with 10 cc lidocaine, 2% diluted 50%
Trial: 8791132
Drug: Aspirin and
RxNorm normalized name: Aspirin and Caffeine Tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin and NSAIDs
Trial: 6349289
Drug: Health motivation
RxNorm normalized name: Healthy Mama
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Health motivation treatment (self-management skills, film model, verbal commitment, discussion of costs and benefits)
Trial: 6349289
Drug: Health motivation
RxNorm normalized name: Healthy Mama
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Health motivation treatment
Trial: 30308287
Drug: Daily drinking
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily drinking
Trial: 30308287
Drug: Confidence to
RxNorm normalized name: miconazole nitrate Topical Cream [Clearly Confident]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Confidence to cope with pain without medication
Trial: 25364993
Drug: Cognitive Behavioral
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Behavioral Therapy for Interoceptive Cues (CBT‐IC)
Trial: 23140210
Drug: Adequate initial
RxNorm normalized name: Adequan
DrugBank: Polysulfated glycosaminoglycan (DB11538)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adequate initial treatment
Trial: 19355795
Drug: Salmeterol-fluticasone propionate
RxNorm normalized name: fluticasone propionate / salmeterol Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salmeterol-fluticasone propionate combination (SFC)
Trial: 15008689
Drug: 42 mg
RxNorm normalized name: lithium 42 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 42 mg transdermal nicotine patch for 4 weeks, followed by 8-week dose titration
Trial: 15008689
Drug: 21 mg
RxNorm normalized name: aspirin 421 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 21 mg transdermal nicotine patch for 4 weeks, followed by 8-week dose titration
Trial: 29425304
Drug: High baseline
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High baseline P1NP (>70 ng/mL)
Trial: 29425304
Drug: High baseline
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High baseline CTX (>0.299 ng/mL)
Trial: 29425304
Drug: High baseline
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High baseline 1‐CTP (>4.2 ng/mL)
Trial: 27552061
Drug: 5 g
RxNorm normalized name: 15 g/31 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 g resveratrol
Trial: 23890368
Drug: Sub-Tenon injection
RxNorm normalized name: tenonitrozole
DrugBank: Tenonitrozole (DB13659)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sub-Tenon injection of 2.5 ml of 2% lidocaine
Trial: 18544974
Drug: Lactobacillus GG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lactobacillus GG (LGG) + 2 g of galacto-oligosaccharides (GOS)
Trial: 14556322
Drug: Intranasal beclomethasone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal beclomethasone
Trial: 9536920
Drug: Vitamin E,
RxNorm normalized name: GRx Vitamin E, topical cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin E, 400 i.u. daily for 8 weeks
Trial: 9536920
Drug: L-arginine (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-arginine (10 mg/min) administration
Trial: 7705152
Drug: Nasal continuous
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nasal continuous positive airway pressure therapy (N-CPAP) at a pressure of 10 cm H2O
Trial: 2705667
Drug: Chlorpromazine (0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chlorpromazine (0.1 mg/kg, repeated every 15 minutes up to three doses)
Trial: 2705667
Drug: Meperidine with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Meperidine with dimenhydrinate (0.4 mg/kg meperidine and 25 mg dimenhydrinate, repeated every 15 minutes up to three doses)
Trial: 26790259
Drug: Sea buckthorn
RxNorm normalized name: sea buckthorn
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sea buckthorn oil treatment once a week
Trial: 26790259
Drug: Sea buckthorn
RxNorm normalized name: sea buckthorn
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sea buckthorn oil treatment
Trial: 8290211
Drug: Trabeculectomy with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trabeculectomy with adjunctive mitomycin C (TMC), n = 35
Trial: 3297772
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of current grading system and SAL (serum albumin loss).
Trial: 22027646
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of micronutrients (Orthomol vital m/f) for three months
Trial: 22027646
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of micronutrients (Orthomol vital m/f)
Trial: 22027646
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of micronutrients (Orthomol vital m/f) in male subjects
Trial: 18218204
Drug: HNPPV group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HNPPV group (n=20) with conventional therapy and HNPPV
Trial: 18218204
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (n=20) with conventional therapy only
Trial: 14767751
Drug: High-dose methotrexate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose methotrexate (HDMTX) only
Trial: 11834237
Drug: Sodium cellulose
RxNorm normalized name: Sodium cellulose phosphate
DrugBank: Sodium cellulose phosphate (DB06776)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sodium cellulose sulfate (CS), 7 consecutive daily doses
Trial: 9568181
Drug: Mistletoe lectin
RxNorm normalized name: MISTLETOE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mistletoe lectin (ML-1) standardized therapy; subcutaneous administration of 0.5-1.0 ng ML-1/kg body weight, twice a week
Trial: 8309029
Drug: Immediate-release (IR)
RxNorm normalized name: IR-3535
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate-release (IR) niacin at 1500 mg/d and above
Trial: 8309029
Drug: Sustained-release (SR)
RxNorm normalized name: Sustained Release Buccal Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sustained-release (SR) niacin at 1500 mg/d and above
Trial: 8309029
Drug: Immediate-release (IR)
RxNorm normalized name: IR-3535
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate-release (IR) niacin
Trial: 8309029
Drug: Sustained-release (SR)
RxNorm normalized name: Sustained Release Buccal Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sustained-release (SR) niacin
Trial: 29614865
Drug: Prednisolone 7.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prednisolone 7.5 mg/d
Trial: 20673994
Drug: Cognitive behaviour
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive behaviour therapy (CBT) for adolescents with mental health problems; details on dosage and duration not specified.
Trial: 8703169
Drug: Low-dose heparin
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose heparin (5000 units, subcutaneously every 12 hours)
Trial: 8703169
Drug: Low-molecular-weight heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-molecular-weight heparin (enoxaparin, 30 mg, subcutaneously every 12 hours)
Trial: 3890872
Drug: Probucol 500
RxNorm normalized name: probucol 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probucol 500 mg b.d. for 3 months
Trial: 29746232
Drug: Educational booklet
RxNorm normalized name: DIABETES PATIENT EDUCATION PACK
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Educational booklet about PTSD treatment
Trial: 24912463
Drug: Internet-delivered cognitive-behavioral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Internet-delivered cognitive-behavioral treatment with motivational support
Trial: 24912463
Drug: Internet-delivered cognitive-behavioral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Internet-delivered cognitive-behavioral treatment without motivational support
Trial: 21771277
Drug: Single dose
RxNorm normalized name: Citrucel Single Dose Packets (Orange)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of rhPTH(1‐84) at 0.5‐5.0 μg/kg
Trial: 21771277
Drug: Single doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single doses of rhPTH(1‐84) at 1.0, 2.0, and 4.0 μg/kg
Trial: 21771277
Drug: Multiple doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple doses of rhPTH(1‐84) at 2.0 μg/kg once daily for 7 days
Trial: 21771277
Drug: Multiple doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple doses of rhPTH(1‐34) at 2.0 μg/kg once daily for 7 days
Trial: 21771277
Drug: Post-dosing at
RxNorm normalized name: rose bengal AT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Post-dosing at 4 hr
Trial: 17391172
Drug: Low-dose tri-iodothyronine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-dose tri-iodothyronine (T3)
Trial: 9133749
Drug: alprazolam 2
RxNorm normalized name: alprazolam 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: alprazolam 2 mg
Trial: 9133749
Drug: alprazolam 6
RxNorm normalized name: Acetylcarnitine/Choline Bitartrate/Cocoa Extract/Gamma Aminobutyric Acid/Ginkgo Biloba Leaf/Glutamic Acid/Grape Seed Extract/Griffonia Seed Extract/Valerian Root Extract/Whey Protein Hydrolysate;Alprazolam 62.5 MG; 0.5 MG Oral Kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: alprazolam 6 mg
Trial: 9133749
Drug: imipramine 225
FDA approved: no
EMA approved: no
PMDA approved: no
Description: imipramine 225 mg
Trial: 7962327
Drug: rhIL-6 infusion
RxNorm normalized name: rhIL-15
DrugBank: Interleukin-15, human recombinant (DB17467)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rhIL-6 infusion (150 micrograms)
Trial: 7962327
Drug: rhIL-6 administered
RxNorm normalized name: rhIL-15
DrugBank: Interleukin-15, human recombinant (DB17467)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rhIL-6 administered sc for 42 consecutive days (150 micrograms)
Trial: 26289497
Drug: Sativex (9‐delta‐tetrahydrocannabinol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sativex (9‐delta‐tetrahydrocannabinol plus cannabidiol) oromucosal spray for 4 weeks (including 2 weeks' titration)
Trial: 26289497
Drug: Placebo for
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo for 4 weeks (including 2 weeks' titration)
Trial: 19881358
Drug: Bezafibrate (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bezafibrate (400 mg/d) added to UDCA
Trial: 16640105
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy with thymosin-alpha1 (1.6 microg three times per week) and lymphoblastoid interferon (5 MIU three times per week)
Trial: 16640105
Drug: Monotherapy with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monotherapy with lymphoblastoid interferon (5 MIU three times per week)
Trial: 9196087
Drug: Inhaled fluticasone
RxNorm normalized name: fluticasone Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled fluticasone propionate (FP) 250 microg twice daily for 6 weeks
Trial: 6423796
Drug: Taurine supplementation
RxNorm normalized name: Taurine
DrugBank: Taurine (DB01956)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Taurine supplementation (10.8 mg/kg/day)
Trial: 2139282
Drug: Recombinant yeast-derived
RxNorm normalized name: YEAST CELL,LIVE DERIVATIVE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recombinant yeast-derived hepatitis B vaccine (YDV)
Trial: 2139282
Drug: Plasma-derived hepatitis
RxNorm normalized name: Haptoglobulin 1/1 (Plasma Derived)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Plasma-derived hepatitis B vaccine (PDV)
Trial: 6343878
Drug: Single-dose trimethoprim-sulfametrole
RxNorm normalized name: sulfametrole / trimethoprim
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-dose trimethoprim-sulfametrole (640 to 3200 mg)
Trial: 6343878
Drug: Five-day trimethoprim-sulfametrole
RxNorm normalized name: sulfametrole / trimethoprim
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Five-day trimethoprim-sulfametrole (160 to 800 mg twice daily)
Trial: 6343878
Drug: Five-day trimethoprim
RxNorm normalized name: Trimethoprim
DrugBank: Trimethoprim (DB00440)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Five-day trimethoprim (200 mg twice daily)
Trial: 22113223
Drug: Morphine-bupivacaine (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphine-bupivacaine (10 mg morphine and 0.5% bupivacaine)
Trial: 22113223
Drug: Tramadol-bupivacaine (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tramadol-bupivacaine (100 mg tramadol and 0.5% bupivacaine)
Trial: 16762960
Drug: Iron sucrose
RxNorm normalized name: Iron Sucrose
DrugBank: Iron sucrose (DB09146)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iron sucrose 30 mg
Trial: 16762960
Drug: Iron sucrose
RxNorm normalized name: Iron Sucrose
DrugBank: Iron sucrose (DB09146)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iron sucrose 100 mg (outflow dialyser line)
Trial: 16762960
Drug: Iron sucrose
RxNorm normalized name: Iron Sucrose
DrugBank: Iron sucrose (DB09146)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iron sucrose 100 mg (inflow dialyser line)
Trial: 15153728
Drug: Unilateral periprostatic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Unilateral periprostatic lidocaine administration
Trial: 15153728
Drug: Intravenous synthetic
RxNorm normalized name: Synthetic camphor
DrugBank: Synthetic camphor (DB14156)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous synthetic opioid (meperidine or tramadol) administration